Xeris Pharmaceuticals reported $1.2M in Interest Income for its fiscal quarter ending in March of 2026.





Interest Income Change Date
Celltrion KRW 779M 157.66M Mar/2026
Dianthus Therapeutics USD 6.26M 2.61M Mar/2026
Eli Lilly USD 65M 25M Sep/2025
Kangmei Pharma CNY 2.44M 635.78K Mar/2026
Knight Therapeutics CAD 2.46M 498K Sep/2024
Laboratorios Farma EUR 139K 42K Jun/2025
Medical Developments International AUD 174K 31K Dec/2024
Nektar Therapeutics USD -0.18 0.07 Sep/2024
Pacira USD 1.93M 365K Mar/2026
Pharma Mar EUR 1.63M 3.17M Dec/2025
Qiagen NV USD 10.56M 9.44M Mar/2026
Sartorius EUR 14.8M 5.3M Jun/2026
Supernus Pharmaceuticals USD 2.38M 359K Mar/2026
Tilray USD 12.83M 20.19M May/2024
Zealand Pharma A/S 74M 28.41M Mar/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 2.73M 3.92M Mar/2026